We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies (NALIRICC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03043547
Recruitment Status : Completed
First Posted : February 6, 2017
Last Update Posted : May 18, 2022
Information provided by (Responsible Party):

Tracking Information
First Submitted Date  ICMJE January 26, 2017
First Posted Date  ICMJE February 6, 2017
Last Update Posted Date May 18, 2022
Actual Study Start Date  ICMJE October 24, 2017
Actual Primary Completion Date December 8, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 2, 2017)
progression-free survival [ Time Frame: approx 42 months ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 2, 2017)
  • Overall survival [ Time Frame: approx 42 months ]
  • Objective tumor response rate (ORR) according to RECIST 1.1 [ Time Frame: approx 42 months ]
    Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)
  • Toxicity/Safety [ Time Frame: approx 42 months ]
    according to Common Terminology Criteria for Adverse Events
  • Health related Quality of Life [ Time Frame: approx 42 months ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: February 2, 2017)
  • biomarkers [ Time Frame: approx 42 months ]
    Ca-19-9, CEA, CRP serum levels
  • Immunohistochemistry of Carboxylesterase (CES) [ Time Frame: approx 42 months ]
  • Analyse whole blood [ Time Frame: approx 42 months ]
    will be collected to potentially identify factors that may correlate with tumour response, sensitivity or resistance to nal-IRI
  • Analyse plasma [ Time Frame: approx 42 months ]
    will be collected to potentially identify factors that may correlate with tumour response, sensitivity or resistance to nal-IRI
Original Other Pre-specified Outcome Measures Same as current
Descriptive Information
Brief Title  ICMJE Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies
Official Title  ICMJE A Randomized Phase II Trial of Nal-IRI and 5-Fluorouracil Compared to 5-Fluorouracil in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies
Brief Summary is an open label, randomized, multicenter phase II trial
Detailed Description The primary objective is to assess the efficacy of nal-IRI in gemcitabine pre-treated patients with advanced, unresectable and metastatic cholangio- and gallbladder carcinoma eligible for treatments after failure to respond to a gemcitabine-based treatment
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Cholangiocarcinoma Non-resectable
  • Cholangiocarcinoma Metastatic
  • Cholangiocarcinoma of the Gallbladder
  • Cholangiocarcinoma Advanced
Intervention  ICMJE
  • Drug: nal-IRI
    nal-IRI [Irinotecan liposome] (80 mg/m2 as a 1.5 hour infusion)
  • Drug: 5-FU
    5-FU [5-Fluorouracil] (2400 mg/m2 as 46 hour infusion)
  • Drug: leucovorin
    leucovorin (400 mg/m2 as 0.5 hour infusion)
Study Arms  ICMJE
  • Experimental: Nal-IRI + 5-FU + leucovorin (Arm A)
    nal-IRI [Irinotecan liposome] (80 mg/m2 as a 1.5 hour infusion), 5-FU [5-Fluorouracil] (2400 mg/m2 as 46 hour infusion) and leucovorin (400 mg/m2 as 0.5 hour infusion) (q2w)
    • Drug: nal-IRI
    • Drug: 5-FU
    • Drug: leucovorin
  • 5-FU + leucovorin (Arm B)
    Control intervention/standard arm: 5-FU (2400 mg/m2 as 46 hour infusion) and leucovorin (400 mg/m2 as 0.5 hour infusion) (q2w)
    • Drug: 5-FU
    • Drug: leucovorin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 2, 2017)
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE March 8, 2022
Actual Primary Completion Date December 8, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Written informed consent incl. participation in translational research and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
  2. Age ≥ 18 years at time of study entry
  3. Histologically or cytologically confirmed, non-resectable, locally advanced or metastatic cholangiocarcinoma or gall bladder carcinoma
  4. Measurable or assessable disease according to RECIST 1.1
  5. Documented disease progression after prior gemcitabine or gemcitabine containing therapy, in locally advanced or metastatic setting. Examples of permitted therapies include, but are not limited to:

    1. Single agent gemcitabine
    2. Any one gemcitabine-based regimen, with or without maintenance gemcitabine
  6. ECOG performance status 0-1
  7. Adequate blood count, liver-enzymes, and renal function:

    • ANC > 1,500 cells/μL without the use of hematopoietic growth factors; and
    • Platelet count ≥ 100 x 10^9/L (>100,000 per mm³) and
    • Hemoglobin > 9 g/dL (blood transfusions are permitted for patients with hemoglobin levels below 9 g/dL)
    • Serum total bilirubin ≤ 3x upper normal limit (ULN) (biliary drainage is allowed for biliary obstruction; elevated bilirubin should be caused by obstruction not impaired liver function as assessed by albumin and INR values):
    • Albumin levels ≥ 3.0 g/dL
    • Patients not receiving therapeutic anticoagulation must have an INR < 1.5 ULN and PTT < 1.5 ULN within 7 days prior to randomization. The use of full dose anticoagulants is allowed as long as the INR or PTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least three weeks at the time of randomization
    • AST (SGOT)/ALT (SGPT) ≤ 5 x institutional upper limit of normal
    • Serum Creatinine ≤ 1.5 x ULN and a calculated glomerular filtration rate ≥ 30 mL per minute
  8. Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of treatment.
  9. Subject is willing and able to comply with the protocol (including contraceptive measures) for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

Exclusion Criteria:

  1. Active CNS metastases (indicated by clinical symptoms, cerebral oedema, steroid requirement, or progressive disease); patient should have been off steroids for at least 28 days prior to starting study therapy
  2. Clinically significant gastrointestinal disorder including bleeding, inflammation, occlusion, or diarrhoea > grade 1
  3. History of any second malignancy in the last 5 years; subjects with prior history of in-situ cancer or basal or squamous cell skin cancer are eligible. Subjects with other malignancies are eligible if they have been continuously disease free for at least 5 years.
  4. Active uncontrolled infection, chronic infectious diseases, immune deficiency syndromes or an unexplained fever > 38.5°C during screening visits or on the first scheduled day of dosing (at the discretion of the investigator, patients with tumour fever may be enrolled), which in the investigator's opinion might compromise the patient's participation in the trial or affect the study outcome.
  5. Premalignant hematologic disorders, e.g. myelodysplastic syndrome
  6. Pre-existing lung disease
  7. Clinically significant cardiovascular disease in (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) 6 months before enrollment
  8. History of hypersensitivity to any of the study drugs or any excipient (nal-IRI, other liposomal products, fluoropyrimidines or leucovorin)
  9. Allogeneic transplantation requiring immunosuppressive therapy or other major immunosuppressive therapy
  10. Severe non-healing wounds, ulcers or bone fractions
  11. Evidence of bleeding diathesis or coagulopathy
  12. Major surgical procedures, except open biopsy, nor significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgical procedure during the course of the study except for surgery of central intravenous line placement for chemotherapy administration.
  13. Medication that is known to interfere with any of the agents applied in the trial.
  14. Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year). [Acceptable methods of contraception are:implants, injectable contraceptives, combined oral contraceptives, intrauterine pessaries (only hormonal devices), sexual abstinence or vasectomy of the partner].
  15. Known Gilbert-Meulengracht syndrome
  16. Any condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
  17. Participation in another clinical study with an investigational product during the last 30 days before inclusion or 5 half-lifes of previously used trial medication, whichever is of longer duration.
  18. Previous enrollment or randomization in the present study (does not include screening failure).
  19. Previous enrollment in the NIFE trial [AIO-YMO/HEP-0315]
  20. Involvement in the planning and/or conduct of the study (applies to both Baxalta staff and/or staff of sponsor and study site)
  21. Patient who might be dependent on the sponsor, site or the investigator
  22. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.
  23. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Germany
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT03043547
Other Study ID Numbers  ICMJE AIO-HEP-0116
2016-003709-33 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party AIO-Studien-gGmbH
Original Responsible Party Same as current
Current Study Sponsor  ICMJE AIO-Studien-gGmbH
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Servier
Investigators  ICMJE
Principal Investigator: Arndt Vogel, Prof. Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover
PRS Account AIO-Studien-gGmbH
Verification Date May 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP